Key facts
- Aetion’s last known valuation is $400.0M (Jul 2025).
- It has raised $203.6M across 2 recorded rounds; the latest was Early Stage VC ($36.4M) in Jan 2018.
- Aetion has filed 2 Form Ds with the SEC since 2017, most recently Apr 2018 ($36.4M sold to 13 investors).
- Status: Acquired/Merged (Operating Subsidiary).
- ·Post-money valuations for all 2 rounds
- ·Watchlist + deal alerts for Aetion
Funding rounds
2 roundsAbout Aetion
Developer of a healthcare analytics platform intended to offer real-world analytics and evidence to transform real-world data into decisions. The company's platform uses everyday clinical and financial interactions of the healthcare system to unlock essential evidence about the effectiveness and value of medical treatments, enabling biopharma clients and payers to collaborate in real-time and develop therapeutic insights so that patients get the required care that is both clinically and cost-effective.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2012
- Employees
- 258
- Website
- aetion.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Aetion doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Aetion shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Aetion in its N-PORT filings yet. We sweep new filings monthly.